ONCT News and Press, Oncternal Therapeutics Inc. From 10/05/21

Androgen Receptor (AR) inhibition is an important therapeutic approach for the treatment of Castration-Resistant Prostate Cancer (CRPC), but AR-escape mechanisms related to the expression of AR splice variants (AR-SV), such as AR-V7, represent a significant unmet need and are a key area...

SAN DIEGO and FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, and Celularity Inc. (“Celularity”) (...

FLORHAM PARK, N.J. and SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“Oncternalȁ...

SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Steven Hamburger, Ph.D. as Senior Vice President of Regulatory Aff...

Oncternal Therapeutics, Inc. (ONCT) Q2 2021 Results Earnings Conference Call August 05, 2021, 5:00 pm ET Company Participants Richard Vincent - Chief Financial Officer James Breitmeyer - President, Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Hartaj...

Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q2 2021 Earnings Call Aug 05, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q2 2021 Earnings Call Tran...

Oncternal Therapeutics (NASDAQ:ONCT): Q2 GAAP EPS of -$0.16. Revenue of $0.88M (+41.9% Y/Y) misses by $0.21M. Press Release For further details see: Oncternal Therapeutics misses on revenue

Presented encouraging interim clinical data for cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) in a poster session at ASCO 2021 Expanded the ongoing Phase 1/2 study to evaluate cirmtuzumab plus ibrutin...

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the BTIG Virtual Biotechnology Conference being held A...

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. fin...